# Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

> **NCT02935205** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Mamta Parikh** · enrollment: 38 (estimated)

## Conditions studied

- Metastatic Prostate Carcinoma
- Recurrent Prostate Carcinoma
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Indomethacin

## Key facts

- **NCT ID:** NCT02935205
- **Lead sponsor:** Mamta Parikh
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01-17
- **Primary completion:** 2024-03
- **Final completion:** 2024-12
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2023-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02935205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02935205, "Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02935205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*